BACKGROUND: There is little information on the prevalence of recreational drug use among UK heterosexual men and women, in particular on use of drugs associated with 'chemsex' within gay communities. The aim of this study was to examine among HIV-negative and HIV-positive heterosexual men and women in England: (i) the prevalence of recreational drug use (including use of drugs associated with chemsex), (ii) socio-economic/lifestyle correlates of drug use, and (iii) the association of drug use with sexual behavior measures and mental health symptoms. METHODS: Data are from the AURAH study of HIV-negative individuals attending sexual health clinics across England (2013-2014) and the ASTRA study of HIV-positive individuals attending HIV outpatient clinics in England (2011-2012). Prevalence of recreational drug use (past three months) and associations are presented separately among the four sample groups: HIV-negative (N = 470) and HIV-positive (N = 373) heterosexual men and HIV-negative (N = 676) and HIV-positive (N = 637) women. RESULTS: The age standardized prevalence of any drug use was 22.9%, 17.1%, 15.3%, and 7.1% in the four sample groups respectively. In all groups, cannabis was the drug most commonly used (range from 4.7% to 17.9%) followed by cocaine (1.6% to 8.5%). The prevalence of use of drugs associated with chemsex was very low among HIV-negative participants (1.0% heterosexual men, 0.2% women) and zero among HIV-positive men and women. In age-adjusted analysis, factors linked to drug use overall and/or to cannabis and cocaine use specifically in the four sample groups included Black/mixed Caribbean and white (vs. Black/mixed African) ethnicity, lower level of education , cigarette smoking, and higher risk alcohol consumption. Associations of recreational drug use with measures of condomless sex, depression, and anxiety were observed in the four groups, but were particularly strong/apparent among women. CONCLUSION: Providers need to be aware of cannabis and cocaine use and its potential link with sexual risk behavior and symptoms of depression and anxiety among heterosexual men and women attending sexual health and HIV clinics.
BACKGROUND: There is little information on the prevalence of recreational drug use among UK heterosexual men and women, in particular on use of drugs associated with 'chemsex' within gay communities. The aim of this study was to examine among HIV-negative and HIV-positive heterosexual men and women in England: (i) the prevalence of recreational drug use (including use of drugs associated with chemsex), (ii) socio-economic/lifestyle correlates of drug use, and (iii) the association of drug use with sexual behavior measures and mental health symptoms. METHODS: Data are from the AURAH study of HIV-negative individuals attending sexual health clinics across England (2013-2014) and the ASTRA study of HIV-positive individuals attending HIV outpatient clinics in England (2011-2012). Prevalence of recreational drug use (past three months) and associations are presented separately among the four sample groups: HIV-negative (N = 470) and HIV-positive (N = 373) heterosexual men and HIV-negative (N = 676) and HIV-positive (N = 637) women. RESULTS: The age standardized prevalence of any drug use was 22.9%, 17.1%, 15.3%, and 7.1% in the four sample groups respectively. In all groups, cannabis was the drug most commonly used (range from 4.7% to 17.9%) followed by cocaine (1.6% to 8.5%). The prevalence of use of drugs associated with chemsex was very low among HIV-negative participants (1.0% heterosexual men, 0.2% women) and zero among HIV-positive men and women. In age-adjusted analysis, factors linked to drug use overall and/or to cannabis and cocaine use specifically in the four sample groups included Black/mixed Caribbean and white (vs. Black/mixed African) ethnicity, lower level of education , cigarette smoking, and higher risk alcohol consumption. Associations of recreational drug use with measures of condomless sex, depression, and anxiety were observed in the four groups, but were particularly strong/apparent among women. CONCLUSION: Providers need to be aware of cannabis and cocaine use and its potential link with sexual risk behavior and symptoms of depression and anxiety among heterosexual men and women attending sexual health and HIV clinics.
Authors: B Hampel; K Kusejko; R D Kouyos; J Böni; M Flepp; M Stöckle; A Conen; C Béguelin; P Künzler-Heule; D Nicca; A J Schmidt; H Nguyen; J Delaloye; M Rougemont; E Bernasconi; A Rauch; H F Günthard; D L Braun; J Fehr Journal: HIV Med Date: 2019-12-18 Impact factor: 3.180
Authors: Ronan W Glynn; Niamh Byrne; Siobhan O'Dea; Adam Shanley; Mary Codd; Eamon Keenan; Mary Ward; Derval Igoe; Susan Clarke Journal: Int J Drug Policy Date: 2017-12-07
Authors: Kurt Kroenke; Robert L Spitzer; Janet B W Williams; Patrick O Monahan; Bernd Löwe Journal: Ann Intern Med Date: 2007-03-06 Impact factor: 25.391
Authors: Janey Sewell; Ada Miltz; Fiona C Lampe; Valentina Cambiano; Andrew Speakman; Andrew N Phillips; David Stuart; Richard Gilson; David Asboe; Nneka Nwokolo; Amanda Clarke; Simon Collins; Graham Hart; Jonathan Elford; Alison J Rodger Journal: Int J Drug Policy Date: 2017-02-10
Authors: Marina Daskalopoulou; Alison J Rodger; Andrew N Phillips; Lorraine Sherr; Jonathan Elford; Jeffrey McDonnell; Simon Edwards; Nicky Perry; Ed Wilkins; Simon Collins; Anne M Johnson; William J Burman; Andrew Speakman; Fiona C Lampe Journal: Sex Transm Infect Date: 2017-07-05 Impact factor: 3.519
Authors: Rachel Margaret Coyle; Ada Rose Miltz; Fiona C Lampe; Janey Sewell; Andrew N Phillips; Andrew Speakman; Jyoti Dhar; Lorraine Sherr; S Tariq Sadiq; Stephen Taylor; Daniel R Ivens; Simon Collins; Jonathan Elford; Jane Anderson; Alison Rodger Journal: Sex Transm Infect Date: 2018-03-08 Impact factor: 3.519
Authors: Daniel Íncera-Fernández; Francisco J Román; Manuel Gámez-Guadix Journal: Int J Environ Res Public Health Date: 2022-05-24 Impact factor: 4.614